A new study at IISc looks to uncover the secret behind the development of drug resistance in TB causing bacteria by testing the efficacy of various commonly available antibiotics. The researchers have found that a combination of commonly available antibiotics along with Augmentin, fights the development of resistance among TB bacteria. This study might throw light on developing new class of drugs that can help contain the spread of deadly tuberculosis, claim the researchers.
You are here
Foodborne diseases, caused by Salmonella, are responsible for 1 in 10 illnesses globally. Treating Salmonella infections using traditional antibiotics is turning to be a challenge because of the development of drug resistant strains. Now, a new study at IISc has developed nanotechnology based nanocarries using silica that can deliver very small dosage of antibiotics to the affected cells, thus hitting the right target. Using laboratory experiments, the researchers found that these nanocarries performed much better than conventional antibiotics in all stages of the infection. The design of these nanocarries are generic, and can be used for delivering different antibiotics, they claim.
A recent report by the World Health Organization estimates that about two million deaths occur every year due to tuberculosis (TB). An alarming dimension to this problem is the fact that some strains of Mycobacterium tuberculosis (Mtb), the causative agent of TB, have developed resistance to some antibiotics used to kill them, leading to the emergence of ‘drug resistant TB’ and causing a global threat. Drug resistance is a way by which bacteria respond to the drug stress they face. Due to improper and irregular use of antibiotics by patients, not all bacteria may be killed, leading to the emergence of drug resistant strains that survive even when further doses of the drug are administered. Now, a team of researchers at the Indian Institute of Science, Bangalore, led by Prof. Nagasuma Chandra and Prof. Amit Singh, have explored the mechanism behind the development of resistance to a front-line anti-tubercular drug called isoniazid, used widely in the clinic.